$LTRN
Lantern Pharma Inc

2024 Q3 Form 10-Q Financial Statement

#000149315224030766 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.520M $1.632M
YoY Change -6.88% 16.08%
% of Gross Profit
Research & Development $3.889M $3.558M
YoY Change 9.29% 19.05%
% of Gross Profit
Depreciation & Amortization $4.260K $3.510K
YoY Change 21.37% 47.48%
% of Gross Profit
Operating Expenses $5.408M $5.190M
YoY Change 4.2% 18.1%
Operating Profit -$5.408M -$5.190M
YoY Change 4.2% 18.1%
Interest Expense $188.7K $117.8K
YoY Change 60.13% 114.1%
% of Operating Profit
Other Income/Expense, Net $260.3K $326.1K
YoY Change -20.17% -313.69%
Pretax Income -$4.960M -$4.746M
YoY Change 4.49% 5.65%
Income Tax
% Of Pretax Income
Net Earnings -$4.960M -$4.746M
YoY Change 4.49% 5.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.46 -$0.44
Diluted Earnings Per Share -$0.46 -$0.44
COMMON SHARES
Basic Shares Outstanding 10.76M shares 10.76M shares 10.86M shares
Diluted Shares Outstanding 10.76M shares 10.86M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.26M $47.95M
YoY Change -30.63% -22.85%
Cash & Equivalents $12.98M $28.42M
Short-Term Investments $20.29M $19.53M
Other Short-Term Assets $2.029M $3.093M
YoY Change -34.38% -11.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.29M $51.04M
YoY Change -30.86% -22.27%
LONG-TERM ASSETS
Property, Plant & Equipment $50.29K $49.95K
YoY Change 0.68% 24.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.02K $25.87K
YoY Change 23.76% 44.61%
Total Long-Term Assets $295.4K $384.1K
YoY Change -23.1% -46.42%
TOTAL ASSETS
Total Short-Term Assets $35.29M $51.04M
Total Long-Term Assets $295.4K $384.1K
Total Assets $35.59M $51.43M
YoY Change -30.8% -22.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.437M $2.853M
YoY Change 55.52% -44.86%
Accrued Expenses $164.0K $163.2K
YoY Change 0.52% 24.82%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.601M $3.016M
YoY Change 52.55% -43.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $54.69K $150.7K
YoY Change -63.71%
Total Long-Term Liabilities $54.69K $150.7K
YoY Change -63.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.601M $3.016M
Total Long-Term Liabilities $54.69K $150.7K
Total Liabilities $4.655M $3.167M
YoY Change 47.01% -40.3%
SHAREHOLDERS EQUITY
Retained Earnings -$65.64M -$47.90M
YoY Change 37.05% 42.39%
Common Stock $1.076K $1.087K
YoY Change -1.01% 0.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.93M $48.26M
YoY Change
Total Liabilities & Shareholders Equity $35.59M $51.43M
YoY Change -30.8% -22.53%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.960M -$4.746M
YoY Change 4.49% 5.65%
Depreciation, Depletion And Amortization $4.260K $3.510K
YoY Change 21.37% 47.48%
Cash From Operating Activities -$5.191M -$3.592M
YoY Change 44.51% 31.45%
INVESTING ACTIVITIES
Capital Expenditures $4.260K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$197.8K -$457.2K
YoY Change -56.74% -10.62%
Cash From Investing Activities -$202.1K -$457.2K
YoY Change -55.81% -13.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -5.191M -3.592M
Cash From Investing Activities -202.1K -457.2K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.393M -4.049M
YoY Change 33.18% 24.27%
FREE CASH FLOW
Cash From Operating Activities -$5.191M -$3.592M
Capital Expenditures $4.260K $0.00
Free Cash Flow -$5.195M -$3.592M
YoY Change 44.63% 32.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001763950
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
usd
LTRN Removal Of Operating Lease Rightofuse Assets And Related Operating Lease Liabilities Upon Early Termination Of Leases
RemovalOfOperatingLeaseRightofuseAssetsAndRelatedOperatingLeaseLiabilitiesUponEarlyTerminationOfLeases
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Lantern Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
001-39318
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3973463
dei Entity Address Address Line1
EntityAddressAddressLine1
1920 McKinney Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75201
dei City Area Code
CityAreaCode
(972)
dei Local Phone Number
LocalPhoneNumber
277-1136
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
LTRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10764725 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12976565 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21937749 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20285554 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19364923 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2029458 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2038653 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
35291577 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
43341325 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50292 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52127 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
213045 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32015 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25869 usd
CY2024Q2 us-gaap Assets
Assets
35586929 usd
CY2023Q4 us-gaap Assets
Assets
43647616 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4436796 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2505211 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164002 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172975 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4600798 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2678186 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54694 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61496 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4655492 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2739682 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10758805 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10758805 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10721192 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10721192 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1076 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1072 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96581666 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96258726 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6585 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-107460 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65644720 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55244404 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30931437 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
40907934 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35586929 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43647616 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1519724 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1632080 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3000939 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3365401 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3888737 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3558217 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8139523 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6111164 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
5408461 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5190297 usd
us-gaap Operating Expenses
OperatingExpenses
11140462 usd
us-gaap Operating Expenses
OperatingExpenses
9476565 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5408461 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5190297 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11140462 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9476565 usd
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
188660 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
117823 usd
us-gaap Interest Income Other
InterestIncomeOther
389610 usd
us-gaap Interest Income Other
InterestIncomeOther
251605 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
260295 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
326076 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
350536 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
610797 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4959506 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
us-gaap Net Income Loss
NetIncomeLoss
-10400316 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10758805 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10758805 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857040 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10750801 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10750801 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10857040 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10857040 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4959506 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4746398 usd
us-gaap Net Income Loss
NetIncomeLoss
-10400316 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
26483 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33763 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
70429 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84536 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-34928 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4077 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
30446 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25013 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8445 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
100875 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
109549 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4967951 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4708558 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10299441 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8504614 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
56038024 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
333530 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3867765 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
71709 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
52575498 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
52575498 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
392390 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37840 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
48259330 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
40907934 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54716 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
134057 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5440810 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
109320 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
35765217 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
35765217 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
134171 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4959506 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8445 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8445 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30931437 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
30931437 usd
us-gaap Net Income Loss
NetIncomeLoss
-10400316 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614163 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8319 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6929 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
83092 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
80272 usd
us-gaap Share Based Compensation
ShareBasedCompensation
268228 usd
us-gaap Share Based Compensation
ShareBasedCompensation
725920 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
93166 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
86578 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50778 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-50633 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
7088 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-60909 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1799 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
12050 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12932 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-415114 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1931888 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
111774 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-83617 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79867 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6146 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7980 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8259161 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7349087 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6484 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8876 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14360080 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5909244 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13608333 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-758231 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1418120 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
54716 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
54716 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1492 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11409 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8961184 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8778616 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21937749 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37742966 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12976565 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28964350 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12976565 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28423170 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
541180 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12976565 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28964350 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
198405 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
141989 usd
LTRN Remeasurement Of Operating Lease Rightofuse Asset And Operating Lease Liability
RemeasurementOfOperatingLeaseRightofuseAssetAndOperatingLeaseLiability
198847 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
70429 usd
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
84536 usd
LTRN Removal Of Operating Lease Rightofuse Assets And Related Operating Lease Liabilities Upon Early Termination Of Leases
RemovalOfOperatingLeaseRightofuseAssetsAndRelatedOperatingLeaseLiabilitiesUponEarlyTerminationOfLeases
130563 usd
us-gaap Net Income Loss
NetIncomeLoss
-10400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8614000 usd
CY2024Q2 LTRN Working Capital
WorkingCapital
30691000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_849_eus-gaap--UseOfEstimates_zboYLPCQ88kf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zmgzkmsatjpi">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining research and development accruals, the inputs in determining the fair value of equity-based awards and warrants issued, the inputs in determining present value of lease payments, and determining the fair value of marketable securities. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_znil7Jx4sVB" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAi3Dsr5AaN">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our marketable securities have had and may in the future have their market value fluctuate due to rises or falls in interest rates. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are federally insured. Interest bearing and non-interest bearing accounts we hold at these banking institutions are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240630__srt--RangeAxis__srt--MaximumMember_zoi3nlTKX5N6" title="Cash FDIC insured amount">250,000</span> per depositor, per FDIC-insured bank, per ownership category. Substantially all of our cash balances held at banking institutions at June 30, 2024 are in excess of FDIC coverage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
11508000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
20881000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
213045 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164002 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172975 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54694 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
61496 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
218696 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
234471 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
92725 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
140216 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
232941 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14245 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
218696 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
164002 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54694 usd
CY2024Q2 us-gaap Short Term Lease Payments
ShortTermLeasePayments
11200 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
228295 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
234471 usd
LTRN Operating Lease Rightofuse Asset Acquired
OperatingLeaseRightofuseAssetAcquired
198405 usd
LTRN Operating Lease Liability Acquired
OperatingLeaseLiabilityAcquired
198405 usd
LTRN Operating Lease Assets Early Termination
OperatingLeaseAssetsEarlyTermination
130563 usd
LTRN Operating Lease Liability Early Termination
OperatingLeaseLiabilityEarlyTermination
130563 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
83092 usd
LTRN Operating Lease Liability Amortization Expense
OperatingLeaseLiabilityAmortizationExpense
83617 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
213045 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
218696 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M21D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M21D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0903 pure
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0736 pure
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
45000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
67000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
90000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
109000 usd
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4800 usd
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
9300 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
49800 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
72000 usd
us-gaap Lease Cost
LeaseCost
99300 usd
us-gaap Lease Cost
LeaseCost
114000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
91000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
111000 usd
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
12000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
63000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
9500 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
2500 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10758805 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10758805 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10721192 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10721192 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1091196 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
20000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
47648 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.99
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1063548 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.14
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
916670 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.23
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
134171 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
392390 usd
us-gaap Share Based Compensation
ShareBasedCompensation
268228 usd
us-gaap Share Based Compensation
ShareBasedCompensation
725920 usd
CY2024Q2 LTRN Available For Sale Securities Amortized Costs
AvailableForSaleSecuritiesAmortizedCosts
20769715 usd
CY2024Q2 LTRN Marketable Securities Unrealized Gains
MarketableSecuritiesUnrealizedGains
979 usd
CY2024Q2 LTRN Marketable Securities Unrealized Losses
MarketableSecuritiesUnrealizedLosses
485140 usd
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20285554 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
14714904 usd
CY2024Q2 LTRN Debt Securities Available For Sale Fair Value Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleFairValuePositionLessThan12MonthsAccumulatedLoss
7886489 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
8690 usd
CY2024Q2 LTRN Debt Securities Available For Sale Continuous Fair Value Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousFairValuePosition12MonthsOrLongerAccumulatedLoss
8230241 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
476450 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
30806762 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1145044 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1268466 shares

Files In Submission

Name View Source Status
0001493152-24-030766-index-headers.html Edgar Link pending
0001493152-24-030766-index.html Edgar Link pending
0001493152-24-030766.txt Edgar Link pending
0001493152-24-030766-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
ltrn-20240630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ltrn-20240630_cal.xml Edgar Link unprocessable
ltrn-20240630_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ltrn-20240630_pre.xml Edgar Link unprocessable
ltrn-20240630_lab.xml Edgar Link unprocessable